Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke
Background. IV tissue plasminogen activator (tPA) is the treatment of choice for ischemic strokes that present within the treatment window. In the majority of patients, this offers an effective and often life-prolonging treatment in the acute setting. In a rare set of patients treated with IV tPA, s...
Saved in:
Main Authors: | Benjamin Chaucer, Dustin Whelan, Christopher Veys, Manas Upadhyaya |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Case Reports in Critical Care |
Online Access: | http://dx.doi.org/10.1155/2018/3257215 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review
by: Archit Bhatt, et al.
Published: (2013-01-01) -
Vitrectomy with subretinal tissue plasminogen activator and intravitreal injection of bevacizumab in the treatment of submacular haemorrhage secondary to wet AMD – case series
by: Agnieszka Nowosielska, et al.
Published: (2024-03-01) -
Acute Ischemic Stroke Secondary to Iron Deficiency Anemia: A Case Report
by: Preema J. Mehta, et al.
Published: (2012-01-01) -
Use of the Recombinant Tissue Plasminogen Activator in the Management of Complex Infected Intraperitoneal Fluid Collection
by: Aibek E. Mirrakhimov, et al.
Published: (2019-01-01) -
Institutional Incidence of Severe tPA-Induced Angioedema in Ischemic Cerebral Vascular Accidents
by: Matthew Sczepanski, et al.
Published: (2018-01-01)